Alkermes ALKS Net debt / EBITDA

Net debt / EBITDA at other companies

Bristol-Myers SquibbBMY

2.3×-0.6×

Jazz PharmaceuticalsJAZZ

5.6×-2.2×

AbbVieABBV

2.5×—

Indivior Pharmaceuticals, Inc.INDV

1×+0.9×

Harmony Biosciences Holdings, Inc.HRMY

-2×+1.3×

Neurocrine BiosciencesNBIX

0.2×-0.3×

FAQ

What is Alkermes's net debt / EBITDA?

Alkermes (ALKS) reported net debt / EBITDA of 5.9× in Q2 2026.

How has Alkermes's net debt / EBITDA changed year-over-year?

Alkermes's net debt / EBITDA increased by 633.3% year-over-year, from -1.1× to 5.9×.

What is the long-term trend for Alkermes's net debt / EBITDA?

Over 3 years (2021 to 2025), Alkermes's net debt / EBITDA has grown at a -12.2% compound annual growth rate (CAGR), from 1.7× to -1.1×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.